Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Protein Expr Purif ; 77(1): 34-45, 2011 May.
Article in English | MEDLINE | ID: mdl-21262364

ABSTRACT

Biomedical research has undergone a major shift in emphasis over the past decade from characterizing the genomes of organisms to characterizing their proteomes. The high-throughput approaches that were successfully applied to sequencing of genomes, such as miniaturization and automation, have been adapted for high-throughput cloning and protein production. High-throughput platforms allow for a multi-construct, multi-parallel approach to expression optimization and construct evaluation. We describe here a series of baculovirus transfer and expression vectors that contain ligation-independent cloning regions originally designed for use in high-throughput Escherichia coli expression evaluation. These new vectors allow for parallel cloning of the same gene construct into a variety of baculovirus or E. coli expression vectors. A high-throughput platform for construct expression evaluation in baculovirus-infected insect cells was developed to utilize these vectors. Data from baculovirus infection expression trials for multiple constructs of two target protein systems relevant to the study of human diseases are presented. The target proteins exhibit a wide variation in behavior and illustrate the benefit of investigating multiple cell types, fusion partners and secretion signals in optimization of constructs and conditions for eukaryotic protein production.


Subject(s)
Baculoviridae/genetics , Cloning, Molecular/methods , DNA, Recombinant/administration & dosage , Spodoptera/metabolism , Spodoptera/virology , Animals , Bacterial Proteins/biosynthesis , Bacterial Proteins/genetics , Cell Line , DNA, Recombinant/genetics , Electrophoresis, Polyacrylamide Gel , Escherichia coli/genetics , Escherichia coli/metabolism , Genetic Vectors/genetics , High-Throughput Screening Assays , Humans , I-kappa B Kinase/biosynthesis , I-kappa B Kinase/genetics , Luminescent Proteins/biosynthesis , Luminescent Proteins/genetics , Reproducibility of Results , Viral Nonstructural Proteins/biosynthesis , Viral Nonstructural Proteins/genetics
2.
Biochemistry ; 43(42): 13380-9, 2004 Oct 26.
Article in English | MEDLINE | ID: mdl-15491144

ABSTRACT

The antibacterial target enoyl-acyl carrier protein (ACP) reductase is a homotetrameric enzyme that catalyzes the last reductive step of fatty acid biosynthesis. In the present paper, four 2-(2-hydroxyphenoxy)phenol inhibitors, wherein the 4-position substituent varied from H to n-propyl, were studied to determine the contribution of the aliphatic chain to the binding to the wild-type (wt) enoyl-ACP reductase from Escherichia coli (FabI) and a drug-resistant mutant, (F203L)FabI, in which phenylalanine 203 is mutated to leucine. Thermodynamic parameters of ternary complex formation (enzyme-NAD(+)-inhibitor) were determined by isothermal titration calorimetry. The inhibitor affinity to wt FabI and (F203L)FabI increases with increasing aliphatic chain length, although the corresponding affinity for (F203L)FabI is lower, and also, it shows no detectable binding to the 4-H inhibitor. A distinguishing feature of inhibitor binding to either binary enzyme-NAD(+) complex is the apparent negative cooperativity for binding to the tetramer with half-site occupancy. For both enzymes, binding is enthalpy, DeltaH, driven. However, binding DeltaH becomes less favorable with increasing aliphatic chain length. Increases in affinity are found to be exclusively due to favorable changes in solvation entropy. Incremental changes in thermodynamic parameters within the series of inhibitors binding to wt FabI and (F203L)FabI are approximately the same. However, absolute differences between the two enzymes for binding to a given inhibitor are significant, suggesting different binding modes. This finding, coupled with a binding site conformation that is likely to be more rigid in the mutant, appears to result in the drug resistance of (F203L)FabI.


Subject(s)
Drug Resistance, Bacterial , Enzyme Inhibitors/chemistry , Escherichia coli Proteins/antagonists & inhibitors , Oxidoreductases/antagonists & inhibitors , Oxidoreductases/chemistry , Point Mutation , Thermodynamics , Binding Sites , Calorimetry , Drug Resistance, Bacterial/drug effects , Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) , Entropy , Enzyme Inhibitors/metabolism , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Fatty Acid Synthases/chemistry , Hot Temperature , Leucine/genetics , Oxidoreductases/genetics , Phenols/chemistry , Phenols/metabolism , Phenylalanine/genetics , Protein Conformation , Protein Folding , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...